Kiromic BioPharma (KRBP) S-1/A 19 Feb 25 2024 FY IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2024
Document Information [Line Items]
Entity Central Index Key	0001792581
Entity Registrant Name	Kiromic Biopharma, Inc.
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Document Type	S-1/A
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4762913
Entity Address, Address Line One	7707 Fannin, Suite 200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77054
City Area Code	832
Local Phone Number	968‑4888
Contact Personnel Name	Pietro Bersani, CPA.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Assets:
Cash and cash equivalents	$ 1,137	$ 3,204
Restricted cash	658	0
Prepaid expenses and other current assets	1,506	1,226
Total current assets	3,301	4,430
Property and equipment, net	4,310	6,175
Operating lease right-of-use asset, net	913	1,543
Other assets	21	21
Total Assets	8,545	12,169
Senior secured convertible promissory notes	13,240	14,000
Accounts payable	2,676	2,136
Accrued expenses and other current liabilities	2,243	1,673
Interest payable	1,645	1,938
Note payable	415	0
Operating lease liability - current	685	631
Total current liabilities	20,904	20,378
Operating lease liability - noncurrent	228	912
Total Liabilities	21,132	21,290
Commitments and contingencies (Note 8)
Stockholders’ Deficit:
Preferred Stock, $0.0001 par value: 60,000,000 shares authorized, 36,835 and 14,000 issued and outstanding, with a liquidation preference of $45,569 and $16,205, as of December 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.001 par value: 300,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 1,533,272 and 1,258,460 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	2	1
Additional paid-in capital	137,206	113,775
Accumulated deficit	(149,795)	(122,897)
Total Stockholders’ Deficit	(12,587)	(9,121)
Total Liabilities and Stockholders’ Deficit	$ 8,545	$ 12,169

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	60,000,000	60,000,000
Preferred stock, issued (in shares)	36,835	14,000
Preferred stock, outstanding (in shares)	36,835	14,000
Preferred stock, liquidation value	$ 45,569	$ 16,205
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	300,000,000	300,000,000
Common stock, issued (in shares)	1,533,272	1,258,460
Common stock, outstanding (in shares)	1,533,272	1,258,460

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
Clinical trials	$ 8,067	$ 2,677
Research and development	6,854	6,948
General and administrative	8,853	10,314
Total operating expenses	23,774	19,939
Loss from operations	(23,774)	(19,939)
Other expense:
Interest expense	(3,723)	(1,852)
Litigation settlement	0	(1,730)
Other income	599	2,572
Total other expense	(3,124)	(1,010)
Net loss	(26,898)	(20,949)
Preferred Stock [Member]
Other expense:
Net loss	$ 0	$ 0
Net loss per share, basic and diluted (in dollars per share)	$ (1,116.47)	$ (1,103.73)
Weighted average shares outstanding, basic and diluted (in shares)	26,069	8,773
Common Stock [Member]
Other expense:
Net loss	$ 0	$ 0
Net loss per share, basic and diluted (in dollars per share)	$ (3.17)	$ (12.59)
Weighted average shares outstanding, basic and diluted (in shares)	1,460,883	1,097,630

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Preferred Stock [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Common Stock [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member] Retained Earnings [Member]	Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member]	Series D Convertible Voting Preferred Stock [Member] Preferred Stock [Member]	Series D Convertible Voting Preferred Stock [Member] Common Stock [Member]	Series D Convertible Voting Preferred Stock [Member] Additional Paid-in Capital [Member]	Series D Convertible Voting Preferred Stock [Member] Retained Earnings [Member]	Series D Convertible Voting Preferred Stock [Member]	Standby Equity Purchase Agreement [Member] Preferred Stock [Member]	Standby Equity Purchase Agreement [Member] Common Stock [Member]	Standby Equity Purchase Agreement [Member] Additional Paid-in Capital [Member]	Standby Equity Purchase Agreement [Member] Retained Earnings [Member]	Standby Equity Purchase Agreement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022																0	648,384
Balance at Dec. 31, 2022																$ 0	$ 1	$ 96,172	$ (101,948)	$ (5,775)
Common stock discount amortization																0	0	345	0	345
Warrants underlying common stock issuance																$ 0	$ 0	(345)	0	(345)
Conversion of subordinated convertible notes into shares of common stock (in shares)	0	329,086
Conversion of subordinated convertible notes into shares of common stock	$ 0	$ 0	$ 2,914	$ 0	$ 2,914
Released restricted stock (in shares)																0	83,973
Released restricted stock																$ 0	$ 0	0	0	0
Issuance of shares (in shares)						14,000	0				0	197,017
Issuance of convertible preferred stock						$ 0	$ 0	$ 14,000	$ 0	$ 14,000
Commitments shares issuance from standby equity purchase agreement											$ 0	$ 0	$ 659	$ 0	$ 659
Stock issuance costs																0	0	(111)	0	(111)
Stock compensation expense																0	0	141	0	141
Net loss																$ 0	$ 0	0	(20,949)	(20,949)
Balance (in shares) at Dec. 31, 2023																14,000	1,258,460
Balance at Dec. 31, 2023																$ 0	$ 1	113,775	(122,897)	(9,121)
Common stock discount amortization																0	0	304	0	304
Warrants underlying common stock issuance																$ 0	$ 0	(304)	0	(304)
Released restricted stock (in shares)																0	274,812
Released restricted stock																$ 0	$ 1	(1)	0	0
Issuance of shares (in shares)						22,835	0
Issuance of convertible preferred stock						$ 0	$ 0	$ 22,835	$ 0	$ 22,835
Stock compensation expense																0	0	597	0	597
Net loss																$ 0	$ 0	0	(26,898)	(26,898)
Balance (in shares) at Dec. 31, 2024																36,835	1,533,272
Balance at Dec. 31, 2024																$ 0	$ 2	$ 137,206	$ (149,795)	$ (12,587)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Cash flows from operating activities:
Net loss	$ (26,898)	$ (20,949)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation	2,234	2,221
Operating lease non-cash expense	630	575
Stock compensation expense	597	141
Senior secured convertible promissory note interest expense	3,781	1,796
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(279)	(179)
Increase (Decrease) in Accounts Payable	537	(5,035)
Accrued expenses and other current liabilities	570	792
Operating lease liability	(630)	(587)
Net cash used for operating activities	(19,458)	(21,225)
Cash flows from investing activities:
Purchases of property and equipment	(366)	(207)
Net cash used for investing activities	(366)	(207)
Cash flows from financing activities:
Proceeds from senior secured convertible note payable	18,000	24,000
Proceeds from issuance of common stock	0	659
Stock issuance costs	0	(111)
Borrowings from note payable	900	0
Repayments of note payable	(485)	(557)
Net cash provided by financing activities	18,415	23,991
Net change in cash and cash equivalents and restricted cash	(1,409)	2,559
Cash and cash equivalents and restricted cash:
Beginning of period	3,204	645
End of period	1,795	3,204
Supplemental disclosures of cash flow information:
Cash paid for interest on note payable	13	56
Non-cash investing and financing activities:
Conversion of accrued interest into subordinated convertible promissory note	1,240	0
Property and equipment in accounts payable	3	53
Deferred financing costs forgiven	0	365
Cash and cash equivalents	1,137	3,204
Restricted cash	658	0
Total cash and cash equivalents and restricted cash	1,795	3,204
Exchange Agreement, Senior Secured Convertible Promissory Note for Preferred Shares [Member]
Non-cash investing and financing activities:
Conversion of debt into convertible preferred stock	20,000	14,000
Conversion of Accrued Interest Into Preferred Stock [Member]
Non-cash investing and financing activities:
Conversion of debt into convertible preferred stock	2,835	0
Conversion of Subordinated Convertible Promissory Notes to Common Stock [Member]
Non-cash investing and financing activities:
Conversion of subordinated convertible promissory notes into common stock	$ 0	$ 2,914

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION Nature of Business Kiromic BioPharma, Inc. and subsidiaries (the “Company” or “We”) is a clinical stage fully integrated biotherapeutics company formed under the Texas Business Organizations Code in December 2012. not We are an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary end-to-end bioinformatic, AI targeting and cGMP-compliant manufacturing technologies to address solid tumors. From a development standpoint, we utilize innovative non-engineered and engineered allogeneic Gamma Delta T (GDT) cell technologies and are developing proprietary, virus-free cell engineering methods to develop novel therapies for solid tumors that we believe will be effective and cost-efficient. 1 Our Deltacel product candidate consists of non-engineered GDTs which we expand, enrich, and activate ex-vivo The Company is developing a novel and virus-independent engineering method, which is expected to support the manufacturing of Isocel and Procel. These respective IND applications are expected to be ready for submission to the FDA in the second 2025 first 2026 Reverse Stock Split March 10, 2023, one Credit Memo December 31, 2023, June 30, 2023. 2023 ● Reduction to accounts payable of $1.10 million ● Reduction of deferred financing costs of $0.36 million ● Increase to other income of $0.74 million Going Concern The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $19.5 million December 31, 2024 December 31, 2024 not twelve Given its projected operating requirements and its existing cash and cash equivalents, management’s plans include evaluating different strategies to obtain the required funding of future operations. These plans may not no not may The consolidated financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2024 not Use of Estimates third Concentrations of Credit Risk and Other Uncertainties may not not The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third Restricted Cash December 31, 2024 December 31, 2023 Property and Equipment Asset Description Estimated Lives Laboratory Equipment 3 - 8 Leasehold Improvements 1 - 7 Office Furniture, Fixtures, and Equipment 5 Software 3 - 5 Internal Use Software Development Costs five December 31, 2024 2023 Impairment of Long-Lived Assets no December 31, 2024 2023 Income Taxes may may Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not The Company records uncertain tax positions in accordance with Accounting Standard Codification (“ASC”) 740, Income Taxes two 1 not 2 not 50 No December 31, 2024 2023 Research and Development Expense The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. The upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not Nonvested Stock Options, Restricted Stock Units and Awards 2017 “2017 2021 “2021 The vesting conditions for stock options and RSUs include annual and monthly vesting. Annual vesting conditions are three The vesting conditions for RSAs include cliff vesting conditions. Certain RSUs vest with a range of 6 to 12 months. When RSUs vest, they are released to the grantee within sixty Stock-Based Compensation 2017 “2017 2021 “2021 718, The Company estimates the grant date fair value of stock options using the Black Scholes model and the assumptions used to value such stock options are determined as follows: Expected Term. not Risk Free Interest Rate. zero Volatility. no Dividend Yield. not zero Common Stock Valuations. Segment Data may Recently Issued Accounting Pronouncements Accounting Standards Adopted Segments . November 2023, No. 2023 07, 280 2023 07 December 15, 2023, December 15, 2024, one Accounting Standards Not Income Taxes December 2023, No. 2023 09, 740 2023 09 December 15, 2024, Income Statement November 2024, 2024 03, 220 2024 03 December 15, 2026, December 15, 2027, Convertible Debt November 2024, 2024 04, 470 2024 04 December 15, 2025,

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	3. NET LOSS PER SHARE Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, RSUs and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares is the same. The following table illustrates the computation of basic and diluted loss per share: Year Ended December 31, (In thousands) 2024 2023 Net loss $ (26,898 ) $ (20,949 ) Less: Initial Public Offering Common Stock discount amortization (58 ) (100 ) Less: Public Offering Common Stock discount amortization (246 ) (245 ) Less: Undeclared dividends attributable to convertible preferred stock (6,530 ) (2,206 ) Net loss attributable to common shareholders $ (33,732 ) $ (23,500 ) Year Ended Year Ended December 31, 2024 December 31, 2023 Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (4,626 ) $ (29,106 ) $ (13,817 ) $ (9,683 ) Weighted average shares outstanding, basic and diluted 1,460,883 26,069 1,097,630 8,773 Basic and diluted net loss per share $ (3.17 ) $ (1,116.47 ) $ (12.59 ) $ (1,103.73 )

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following at: (In thousands) December 31, 2024 December 31, 2023 Equipment $ 3,336 $ 3,126 Leasehold improvements 7,372 7,372 Office furniture, fixtures, and equipment 137 137 Software 604 360 Construction in progress 16 101 11,465 11,096 Less: Accumulated depreciation (7,155 ) (4,921 ) Total $ 4,310 $ 6,175 Depreciation expense was $2,234 thousand and $2,221 thousand for the years ended December 31, 2024 2023

Note 5 - Accrued Expenses and O

Note 5 - Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following at: (In thousands) December 31, 2024 December 31, 2023 Accrued litigation and settlements $ — $ 448 Accrued bonuses and compensation 1,780 865 Accrued consulting and outside services 463 360 Total $ 2,243 $ 1,673

Note 6 - Note Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Short-Term Debt [Text Block]	6. NOTE PAYABLE In January 2024, ten December 31, 2024, In November 2024, eleven December 31, 2024,

Note 7 - Senior Secured Convert

Note 7 - Senior Secured Convertible Promissory Note	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	7. SENIOR SECURED CONVERTIBLE PROMISSORY NOTE The Company began issuing senior secured convertible promissory notes (each a “CPN” and together the “Notes”) payable to a private accredited investor (the “Investor”) during 2022. December 31, 2024 2023 Through December 31, 2024 twenty three December 31, 2024 December 31, 2023 thirteen December 31, 2023 25% one 10 The stated interest rates for these notes increase to 27% per annum or the highest rate then allowed under applicable law (whichever is lower) upon the occurrence of an event of default, including the failure by the Company to make payment of principal or interest due under the related note on the respective maturity date, and any commencement by the Company of a case under any applicable bankruptcy or insolvency law. See Note 10 (In thousands) Reclassification Date Principal Amount Accrued Interest Reclassified Total Amount Reclassified Series C 3/28/2023 $ 8,000 $ - $ 8,000 Series C 7/18/2023 6,000 - 6,000 Series D 3/28/2024 8,000 - 8,000 Series D 6/21/2024 7,200 1,638 8,838 Series E 9/27/2024 2,400 597 2,997 Series E 11/1/2024 2,400 600 3,000 Total $ 34,000 $ 2,835 $ 36,835 The CPNs outstanding as of December 31, 2024 2023 (In thousands) Issue Date Maturity Date December 31, 2024 December 31, 2023 06/26/2023 06/26/2024 $ — $ 2,400 07/25/2023 07/25/2024 — 2,400 08/25/2023 08/25/2024 — 2,400 09/27/2023 09/27/2024 — 2,400 11/02/2023 11/02/2024 — 2,400 12/12/2023 12/12/2024 — 2,000 04/02/2024 04/02/2025 2,000 — 05/02/2024 05/02/2025 2,000 — 06/03/2024 06/03/2025 2,000 — 06/21/2024 06/21/2025 1,240 — 07/03/2024 07/03/2025 2,000 — 08/01/2024 08/01/2025 2,000 — 12/09/2024 12/09/2025 2,000 Total senior secured convertible promissory notes $ 13,240 $ 14,000

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES License Agreements one December 31, 2024 2023 not Legal Proceedings Jason Terrel Claim On March 22, 2021, No. 2021 0248 2014 January 2017 On January 31, 2024, 2021, third not On March 11, 2024, January 31, 2024, May 9, 2024; June 25, 2024. October 30, 2024, On January 21, 2025, second not not not December 31, 2024 2023. Karp and Podmore Class Actions On August 5, 2022, July 2, 2021, 11, 12, 15 1933 July 2, 2021 10 1934 10b 5 June 25, 2021 August 13, 2021. On October 3, 2022, The Karp Class Action and the Podmore Class Action are collectively referred to as the “Class Action”. Please refer to the Settlement in Principle of the Class Action described more fully below. Settlement in Principle of the Class Action On August 7, 2023, September 29, 2023, December 31, 2024 December 31, 2023 SEC Settlement On December 3, 2024, May 2021. not no The Company regularly assesses all contingencies and believes, based on information presently known, the Company is not

Note 9 - Leases

Note 9 - Leases	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. LEASES The Company leases real estate for office and warehouse space under non-cancelable operating leases, with a total rentable space of 149,000 square feet. The Company intends to use the full lease term under the existing lease agreement which is currently set to expire on April 30, 2026. December 31, 2024 not There are no variable payments associated with the lease agreements, as the rent payments are predetermined on a fixed schedule. The following table indicates the balance sheet line items that include the right-of-use assets and lease liabilities for our operating lease: (In thousands) December 31, 2024 December 31, 2023 Operating lease Operating lease Right-of-Use Asset Operating lease, net $ 913 $ 1,543 Total right-of use asset, net $ 913 $ 1,543 Lease Liabilities Operating lease - current $ (685 ) $ (631 ) Operating lease - noncurrent (228 ) (912 ) Total lease liabilities $ (913 ) $ (1,543 ) For the year ended December 31, 2024 December 31, 2023 Year Ended (In thousands) December 31, 2024 December 31, 2023 Operating lease cost allocated to clinical trials expense $ 240 $ 110 Operating lease cost allocated to research and development expense 233 284 Operating lease cost allocated to general and administrative expense 243 322 Total lease expense $ 716 $ 716 Weighted-average remaining lease term 1.34 2.34 Weighted-average discount rate 7.12 % 7.12 % As of December 31, 2024 Maturity of Lease Liabilities (In thousands) Operating lease 2025 $ 725 2026 243 Total lease payments 968 Less: imputed interest (55 ) Present value of lease payments $ 913

Note 10 - Stockholders' Deficit

Note 10 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Equity [Text Block]	10. STOCKHOLDERS DEFICIT Common Stock one Preferred Stock December 31, 2024 2023 1 none December 31, 2024 2023 April 2, 2023, July 18, 2023, March 28, 2024, June 21, 2024, September 27, 2024, November 1, 2024. As discussed in Note 7, two 2024, three 5 fifth one one Cumulative Rights of Series C, D and E Stock Shareholders Dividends Earned for the Year Ended Liquidation Preference (In thousands) December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Series C $ 3,510 $ 2,206 $ 19,715 $ 16,205 Series D 2,698 - 19,535 - Series E 322 - 6,319 - Total $ 6,530 $ 2,206 $ 45,569 $ 16,205 Participating Rights of Series C, D and E Stock Shareholders Warrants five may October 14, 2025, July 1, 2026. Standby Equity Purchase Agreement Financing On October 13, 2022, October 13, 2022. November 3, 2024. On May 24, 2023, On June 2, 2023,

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. STOCK-BASED COMPENSATION 2017 Restricted Stock Units The following table summarizes the activity for all RSUs outstanding under the 2017 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 320 $ 285.36 650 $ 259.50 Granted — — — — Vested (64 ) 260.18 (273 ) 255.85 Cancelled and forfeited (252 ) 254.10 (57 ) 260.10 Nonvested RSUs as of December 31 4 $ 257.10 320 $ 285.36 In addition, the weighted average remaining recognition period for the 2017 December 31, 2024 Total stock compensation expense recognized from stock-based compensation awards classified as restricted stock units under the 2017 December 31, 2024 2023 Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 1 $ 7 Research and development 8 19 General and administrative 15 32 Total $ 24 $ 58 As of December 31, 2024 2017 2017 Stock Options The following table summarizes the activity for all stock options outstanding at December 31 2017 2024 2023 Weighted Weighted Average Average Exercise Exercise Shares Price Shares Price Options outstanding at beginning of period 18,093 $ 101.04 32,706 $ 96.24 Granted — — — — Exercised — — — — Cancelled and forfeited (4,372 ) 101.04 (14,613 ) 88.17 Balance as of December 31 13,721 $ 101.04 18,093 $ 101.04 Options exercisable as of December 31: 13,721 $ 101.04 18,093 $ 101.04 The stock options have no December 31, 2024 December 31, 2023 There was no December 31, 2024 2023 As of December 31, 2024 2021 Restricted Stock Units The following table summarizes the activity for all RSUs outstanding under as of December 31, 2024 2023 2021 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 54,706 $ 1.56 684 $ 133.20 Granted 98,944 2.58 138,343 1.45 Vested (22,332 ) 4.11 (83,700 ) 0.23 Cancelled and forfeited (73,116 ) 1.90 (621 ) 126.60 Nonvested RSUs as of December 31 58,202 $ 3.63 54,706 $ 1.56 In addition, the weighted average remaining recognition period for the 2021 December 31, 2024 Total stock compensation expense recognized from stock-based compensation awards classified as RSUs under the 2021 December 31, 2024 2023 Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 32 $ 11 Research and development 26 27 General and administrative 25 45 Total $ 83 $ 83 As of December 31, 2024 2021 2024 December 31, 2023 December 31, 2024 2024 December 31, 2024 2021 Restricted Stock Awards The Company provides its executives and directors with Restricted Stock Awards (“RSAs”) as part of their compensation package. RSAs grant the holder voting rights and dividend participation and vest over a specified term. The following table summarizes the activity for all RSAs outstanding at December 31, 2024 2021 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Nonvested RSAs at beginning of period — $ — — $ — Granted 254,185 2.42 — — Vested (50,361 ) 2.47 — — Cancelled and forfeited — — — — Nonvested RSAs as of December 31 203,824 $ 2.41 — $ — In addition, the weighted average remaining recognition period for the RSAs is 0.24 years. All RSAs granted during 2024 December 31, 2024 2024 2021 December 31, 2024 December 31, 2023 Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 72 $ — Research and development 110 — General and administrative 308 — Total $ 490 $ — As of December 31, 2024

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. INCOME TAXES For the years ended December 31, 2024 2023 no The provision for income taxes during the reporting periods is calculated by applying an estimate of the annual effective tax rate for the full fiscal year to “ordinary” income or loss for the reporting period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws, business reorganizations and settlements with taxing authorities. The Company has recorded the full valuation allowance based on an evaluation of both positive and negative evidence, including latest forecasts and cumulative losses in recent years. The Company has concluded that it was more likely than not none The following is a reconciliation of the effective income tax rate to the statutory federal income tax rate for the years ended December 31, 2024 2023 2024 2023 Federal income tax at statutory rates 21.00 % 21.00 % Federal income tax rate reduction — % — % Change in valuation allowance (21.00 ) (21.00 ) Effective income tax rate — % — % Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. The Company recorded a valuation allowance to fully offset the net deferred tax asset, because it is more likely than not not December 31, 2024 2023 The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows as of December 31: 2024 2023 Deferred tax assets (liabilities): Net operating loss carryforward $ 19,519 $ 16,178 Stock compensation expense 517 471 Research and development tax credit 2,615 2,156 Sec. 174 Research and development expense 4,991 3,207 Property and equipment 482 260 Intangible assets 75 82 Lease liability 192 324 Accrued expenses 327 139 Total gross deferred tax assets 28,718 22,817 Valuation allowance (28,526 ) (22,493 ) Right-of-use assets (192 ) (324 ) Net deferred tax assets (liabilities) — — As of December 31, 2024 2023 2036. may The NOL carryforwards may 382 382" As of December 31, 2024 2023 no not twelve As of December 31, 2024 not

Note 13 - Company 401-K Plan

Note 13 - Company 401-K Plan	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Defined Benefit Plan [Text Block]	13. COMPANY 401 The Company has a defined contribution 401 December 31, 2024 December 31, 2023,

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Dec. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS Issuance of Senior Secured Convertible Promissory Note On January 28, 2025, The Subsequent Note is convertible into shares of the Company’s common stock, par value $0.001 per share, at a floating conversion price equal to 90% of the 5 fifth

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). All intercompany balances were eliminated upon consolidation. Operating results for the year ended December 31, 2024 not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates third
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Other Uncertainties may not not The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash December 31, 2024 December 31, 2023
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Asset Description Estimated Lives Laboratory Equipment 3 - 8 Leasehold Improvements 1 - 7 Office Furniture, Fixtures, and Equipment 5 Software 3 - 5
Internal Use Software, Policy [Policy Text Block]	Internal Use Software Development Costs five December 31, 2024 2023
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets no December 31, 2024 2023
Income Tax, Policy [Policy Text Block]	Income Taxes may may Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not The Company records uncertain tax positions in accordance with Accounting Standard Codification (“ASC”) 740, Income Taxes two 1 not 2 not 50 No December 31, 2024 2023
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. The upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not
Share-Based Payment Arrangement [Policy Text Block]	Nonvested Stock Options, Restricted Stock Units and Awards 2017 “2017 2021 “2021 The vesting conditions for stock options and RSUs include annual and monthly vesting. Annual vesting conditions are three The vesting conditions for RSAs include cliff vesting conditions. Certain RSUs vest with a range of 6 to 12 months. When RSUs vest, they are released to the grantee within sixty Stock-Based Compensation 2017 “2017 2021 “2021 718, The Company estimates the grant date fair value of stock options using the Black Scholes model and the assumptions used to value such stock options are determined as follows: Expected Term. not Risk Free Interest Rate. zero Volatility. no Dividend Yield. not zero Common Stock Valuations.
Segment Reporting, Policy [Policy Text Block]	Segment Data may
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Accounting Standards Adopted Segments . November 2023, No. 2023 07, 280 2023 07 December 15, 2023, December 15, 2024, one Accounting Standards Not Income Taxes December 2023, No. 2023 09, 740 2023 09 December 15, 2024, Income Statement November 2024, 2024 03, 220 2024 03 December 15, 2026, December 15, 2027, Convertible Debt November 2024, 2024 04, 470 2024 04 December 15, 2025,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]	Asset Description Estimated Lives Laboratory Equipment 3 - 8 Leasehold Improvements 1 - 7 Office Furniture, Fixtures, and Equipment 5 Software 3 - 5

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (In thousands) 2024 2023 Net loss $ (26,898 ) $ (20,949 ) Less: Initial Public Offering Common Stock discount amortization (58 ) (100 ) Less: Public Offering Common Stock discount amortization (246 ) (245 ) Less: Undeclared dividends attributable to convertible preferred stock (6,530 ) (2,206 ) Net loss attributable to common shareholders $ (33,732 ) $ (23,500 ) Year Ended Year Ended December 31, 2024 December 31, 2023 Common Stock Preferred Stock Common Stock Preferred Stock Net loss per share, basic and diluted Allocation of undistributed net loss $ (4,626 ) $ (29,106 ) $ (13,817 ) $ (9,683 ) Weighted average shares outstanding, basic and diluted 1,460,883 26,069 1,097,630 8,773 Basic and diluted net loss per share $ (3.17 ) $ (1,116.47 ) $ (12.59 ) $ (1,103.73 )

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	(In thousands) December 31, 2024 December 31, 2023 Equipment $ 3,336 $ 3,126 Leasehold improvements 7,372 7,372 Office furniture, fixtures, and equipment 137 137 Software 604 360 Construction in progress 16 101 11,465 11,096 Less: Accumulated depreciation (7,155 ) (4,921 ) Total $ 4,310 $ 6,175

Note 5 - Accrued Expenses and_2

Note 5 - Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(In thousands) December 31, 2024 December 31, 2023 Accrued litigation and settlements $ — $ 448 Accrued bonuses and compensation 1,780 865 Accrued consulting and outside services 463 360 Total $ 2,243 $ 1,673

Note 7 - Senior Secured Conve_2

Note 7 - Senior Secured Convertible Promissory Note (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Debt Conversions [Table Text Block]	(In thousands) Reclassification Date Principal Amount Accrued Interest Reclassified Total Amount Reclassified Series C 3/28/2023 $ 8,000 $ - $ 8,000 Series C 7/18/2023 6,000 - 6,000 Series D 3/28/2024 8,000 - 8,000 Series D 6/21/2024 7,200 1,638 8,838 Series E 9/27/2024 2,400 597 2,997 Series E 11/1/2024 2,400 600 3,000 Total $ 34,000 $ 2,835 $ 36,835
Convertible Debt [Table Text Block]	(In thousands) Issue Date Maturity Date December 31, 2024 December 31, 2023 06/26/2023 06/26/2024 $ — $ 2,400 07/25/2023 07/25/2024 — 2,400 08/25/2023 08/25/2024 — 2,400 09/27/2023 09/27/2024 — 2,400 11/02/2023 11/02/2024 — 2,400 12/12/2023 12/12/2024 — 2,000 04/02/2024 04/02/2025 2,000 — 05/02/2024 05/02/2025 2,000 — 06/03/2024 06/03/2025 2,000 — 06/21/2024 06/21/2025 1,240 — 07/03/2024 07/03/2025 2,000 — 08/01/2024 08/01/2025 2,000 — 12/09/2024 12/09/2025 2,000 Total senior secured convertible promissory notes $ 13,240 $ 14,000

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Lessee, Operating Lease [Table Text Block]	(In thousands) December 31, 2024 December 31, 2023 Operating lease Operating lease Right-of-Use Asset Operating lease, net $ 913 $ 1,543 Total right-of use asset, net $ 913 $ 1,543 Lease Liabilities Operating lease - current $ (685 ) $ (631 ) Operating lease - noncurrent (228 ) (912 ) Total lease liabilities $ (913 ) $ (1,543 )
Lease, Cost [Table Text Block]	Year Ended (In thousands) December 31, 2024 December 31, 2023 Operating lease cost allocated to clinical trials expense $ 240 $ 110 Operating lease cost allocated to research and development expense 233 284 Operating lease cost allocated to general and administrative expense 243 322 Total lease expense $ 716 $ 716 Weighted-average remaining lease term 1.34 2.34 Weighted-average discount rate 7.12 % 7.12 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Maturity of Lease Liabilities (In thousands) Operating lease 2025 $ 725 2026 243 Total lease payments 968 Less: imputed interest (55 ) Present value of lease payments $ 913

Note 10 - Stockholders' Defic_2

Note 10 - Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Stock by Class [Table Text Block]	Dividends Earned for the Year Ended Liquidation Preference (In thousands) December 31, 2024 December 31, 2023 December 31, 2024 December 31, 2023 Series C $ 3,510 $ 2,206 $ 19,715 $ 16,205 Series D 2,698 - 19,535 - Series E 322 - 6,319 - Total $ 6,530 $ 2,206 $ 45,569 $ 16,205

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 320 $ 285.36 650 $ 259.50 Granted — — — — Vested (64 ) 260.18 (273 ) 255.85 Cancelled and forfeited (252 ) 254.10 (57 ) 260.10 Nonvested RSUs as of December 31 4 $ 257.10 320 $ 285.36 2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Outstanding RSUs at beginning of period 54,706 $ 1.56 684 $ 133.20 Granted 98,944 2.58 138,343 1.45 Vested (22,332 ) 4.11 (83,700 ) 0.23 Cancelled and forfeited (73,116 ) 1.90 (621 ) 126.60 Nonvested RSUs as of December 31 58,202 $ 3.63 54,706 $ 1.56
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 1 $ 7 Research and development 8 19 General and administrative 15 32 Total $ 24 $ 58 Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 32 $ 11 Research and development 26 27 General and administrative 25 45 Total $ 83 $ 83 Year Ended December 31, (In thousands) 2024 2023 Clinical trials $ 72 $ — Research and development 110 — General and administrative 308 — Total $ 490 $ —
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	2024 2023 Weighted Weighted Average Average Exercise Exercise Shares Price Shares Price Options outstanding at beginning of period 18,093 $ 101.04 32,706 $ 96.24 Granted — — — — Exercised — — — — Cancelled and forfeited (4,372 ) 101.04 (14,613 ) 88.17 Balance as of December 31 13,721 $ 101.04 18,093 $ 101.04 Options exercisable as of December 31: 13,721 $ 101.04 18,093 $ 101.04
Nonvested Restricted Stock Shares Activity [Table Text Block]	2024 2023 Weighted Average Weighted Average Grant Date Grant Date Fair Value Fair Value Shares Per Share Shares Per Share Nonvested RSAs at beginning of period — $ — — $ — Granted 254,185 2.42 — — Vested (50,361 ) 2.47 — — Cancelled and forfeited — — — — Nonvested RSAs as of December 31 203,824 $ 2.41 — $ —

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2024 2023 Federal income tax at statutory rates 21.00 % 21.00 % Federal income tax rate reduction — % — % Change in valuation allowance (21.00 ) (21.00 ) Effective income tax rate — % — %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2024 2023 Deferred tax assets (liabilities): Net operating loss carryforward $ 19,519 $ 16,178 Stock compensation expense 517 471 Research and development tax credit 2,615 2,156 Sec. 174 Research and development expense 4,991 3,207 Property and equipment 482 260 Intangible assets 75 82 Lease liability 192 324 Accrued expenses 327 139 Total gross deferred tax assets 28,718 22,817 Valuation allowance (28,526 ) (22,493 ) Right-of-use assets (192 ) (324 ) Net deferred tax assets (liabilities) — —

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) $ in Thousands		6 Months Ended	12 Months Ended		145 Months Ended
	Mar. 10, 2023	Jun. 30, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)
Revenue from Contract with Customer, Excluding Assessed Tax					$ 0
Increase (Decrease) in Accounts Payable			$ 537	$ (5,035)
Deferred Debt Issuance Cost, Writeoff			0	365
Net Cash Provided by (Used in) Operating Activities			(19,458)	(21,225)
Retained Earnings (Accumulated Deficit)			$ (149,795)	(122,897)	$ (149,795)
Credit Memo [Member]
Increase (Decrease) in Accounts Payable		$ 1,100		(1,100)
Deferred Debt Issuance Cost, Writeoff				360
Other Nonoperating Income				$ 740
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	30

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended		145 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024
Restricted Cash	$ 658	$ 0	$ 658
Impairment, Long-Lived Asset, Held-for-Use			0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	0	0
Dividends Payable	$ 0		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%
Number of Reportable Segments	1
Options and RSUs [Member] | Share-based Payment Arrangement, Annual Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	3 years
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Software and Software Development Costs [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years		5 years
Capitalized Computer Software, Additions	$ 260	$ 92
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	1 year		1 year
Minimum [Member] | Options and RSUs [Member] | Share-based Payment Arrangement, Monthly Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	10 months
Minimum [Member] | Restricted Stock Units (RSUs) [Member] | Cliff Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	6 months
Minimum [Member] | Software and Software Development Costs [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	8 years		8 years
Maximum [Member] | Options and RSUs [Member] | Share-based Payment Arrangement, Monthly Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	48 months
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | Cliff Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	12 months
Maximum [Member] | Software and Software Development Costs [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years		5 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Schedule Of Estimated Useful Lives Of Property And Equipment (Details)	Dec. 31, 2024
Minimum [Member]
Useful life (Year)	1 year
Maximum [Member]
Useful life (Year)	8 years
Equipment [Member] | Minimum [Member]
Useful life (Year)	3 years
Equipment [Member] | Maximum [Member]
Useful life (Year)	8 years
Leasehold Improvements [Member] | Minimum [Member]
Useful life (Year)	1 year
Leasehold Improvements [Member] | Maximum [Member]
Useful life (Year)	7 years
Office Furniture, Fixtures, and Equipment [Member]
Useful life (Year)	5 years
Software and Software Development Costs [Member]
Useful life (Year)	5 years
Software and Software Development Costs [Member] | Minimum [Member]
Useful life (Year)	3 years
Software and Software Development Costs [Member] | Maximum [Member]
Useful life (Year)	5 years

Note 3 - Net Loss Per Share - S

Note 3 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Net loss	$ (26,898)	$ (20,949)
Less: Undeclared dividends attributable to convertible preferred stock	(6,530)	(2,206)
Net loss attributable to common shareholders	(33,732)	(23,500)
IPO [Member]
Less: Public Offering Common Stock discount amortization	(58)	(100)
Public Offering [Member]
Less: Public Offering Common Stock discount amortization	(246)	(245)
Common Stock [Member]
Net loss	0	0
Allocation of undistributed net loss	$ (4,626)	$ (13,817)
Weighted average shares outstanding, basic and diluted (in shares)	1,460,883	1,097,630
Basic and diluted net loss per share (in dollars per share)	$ (3.17)	$ (12.59)
Preferred Stock [Member]
Net loss	$ 0	$ 0
Allocation of undistributed net loss	$ (29,106)	$ (9,683)
Weighted average shares outstanding, basic and diluted (in shares)	26,069	8,773
Basic and diluted net loss per share (in dollars per share)	$ (1,116.47)	$ (1,103.73)

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 2,234	$ 2,221

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Equipment	$ 3,336	$ 3,126
Leasehold improvements	7,372	7,372
Office furniture, fixtures, and equipment	137	137
Software	604	360
Construction in progress	16	101
Property, Plant and Equipment, Gross	11,465	11,096
Less: Accumulated depreciation	(7,155)	(4,921)
Total	$ 4,310	$ 6,175

Note 5 - Accrued Expenses and_3

Note 5 - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Accrued litigation and settlements	$ 0	$ 448
Accrued bonuses and compensation	1,780	865
Accrued consulting and outside services	463	360
Total	$ 2,243	$ 1,673

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - Insurance Policy Financing Arrangement [Member] - Notes Payable [Member] - USD ($) $ in Thousands	1 Months Ended
	Nov. 30, 2024	Dec. 31, 2024	Jan. 31, 2024
Debt Instrument, Face Amount	$ 500		$ 400
Debt Instrument, Interest Rate, Stated Percentage	9.06%		8.86%
Debt Instrument, Term (Month)	11 months
Notes Payable		$ 415

Note 7 - Senior Secured Conve_3

Note 7 - Senior Secured Convertible Promissory Note (Details Textual) - Senior Secured Convertible Promissory Note [Member] $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt Instrument, Convertible, Number Issued	23	13
Debt Instrument, Face Amount	$ 47.2	$ 28
Proceeds from Issuance of Debt	$ 19.2	$ 24.2
Debt Instrument, Interest Rate, Stated Percentage	25%
Debt Instrument, Term (Month)	1 year
Debt Instrument, Interest Rate, Maximum Default Percentage	27%

Note 7 - Senior Secured Conve_4

Note 7 - Senior Secured Convertible Promissory Note - Schedule of Debt Conversions (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Nov. 01, 2024	Sep. 27, 2024	Jun. 21, 2024	Mar. 28, 2024	Jul. 18, 2023	Mar. 28, 2023
Original debt principle amount	$ 34,000
Accrued interest reclassified	2,835
Reclassified debt amount	$ 36,835
Convertible Promissory Note Reclassified Into Series C Preferred Stock [Member]
Original debt principle amount						$ 6,000	$ 8,000
Accrued interest reclassified						0	0
Reclassified debt amount						$ 6,000	$ 8,000
Convertible Promissory Note Reclassified Into Series D Preferred Stock [Member]
Original debt principle amount				$ 7,200	$ 8,000
Accrued interest reclassified				1,638	0
Reclassified debt amount				$ 8,838	$ 8,000
Convertible Promissory Note Reclassified Into Series E Preferred Stock [Member]
Original debt principle amount		$ 2,400	$ 2,400
Accrued interest reclassified		600	597
Reclassified debt amount		$ 3,000	$ 2,997

Note 7 - Senior Secured Conve_5

Note 7 - Senior Secured Convertible Promissory Note - Schedule of Convertible Notes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Convertible promissory note	$ 13,240	$ 14,000
Senior Secured Convertible Promissory Notes 1 [Member]
Maturity date	Jun. 26, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 2 [Member]
Maturity date	Jul. 25, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 3 [Member]
Maturity date	Aug. 25, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 4 [Member]
Maturity date	Sep. 27, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 5 [Member]
Maturity date	Nov. 02, 2024
Convertible promissory note	$ 0	2,400
Senior Secured Convertible Promissory Notes 6 [Member]
Maturity date	Dec. 12, 2024
Convertible promissory note	$ 0	2,000
Senior Secured Convertible Promissory Notes 7 [Member]
Maturity date	Apr. 02, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 8 [Member]
Maturity date	May 02, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 9 [Member]
Maturity date	Jun. 03, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 10 [Member]
Maturity date	Jun. 21, 2025
Convertible promissory note	$ 1,240	0
Senior Secured Convertible Promissory Notes 11 [Member]
Maturity date	Jul. 03, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 12 [Member]
Maturity date	Aug. 01, 2025
Convertible promissory note	$ 2,000	0
Senior Secured Convertible Promissory Notes 13 [Member]
Maturity date	Dec. 09, 2025
Convertible promissory note	$ 2,000

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	Sep. 29, 2023	Aug. 07, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 22, 2021
Estimated Litigation Liability, Current			$ 0	$ 448,000
Karp and Podmore Class Actions [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 1,730,000	$ 2,300,000
Insurance Settlements Receivable	$ 570,000
Estimated Litigation Liability, Current				448,000
Licensing Agreements [Member] | Other Commitments, Contingent Milestone Payments [Member]
Other Commitment			$ 0	$ 0
The 2014 Consulting Agreement [Member] | Jason Terrel Claim [Member]
Loss Contingency, Damages Sought, Shares (in shares)					16,667
Loss Contingency, Damages Sought, Shares Issued Price Per Share					$ 15
The January 2017 Options Agreement [Member] | Jason Terrel Claim [Member]
Loss Contingency, Damages Sought, Shares (in shares)					16,667
Loss Contingency, Damages Sought, Shares Issued Price Per Share					$ 5.1

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) ft²
Net Rentable Area (Square Foot) | ft²	149,000
Variable Lease, Payment | $	$ 0

Note 9 - Leases - Schedule of O

Note 9 - Leases - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Operating lease right-of-use asset, net	$ 913	$ 1,543
Operating lease - current	(685)	(631)
Operating lease - noncurrent	(228)	(912)
Total lease liabilities	$ (913)	$ (1,543)

Note 9 - Leases - Schedule of C

Note 9 - Leases - Schedule of Components of Operating Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating lease expense	$ 716	$ 716
Weighted-average remaining lease term (Year)	1 year 4 months 2 days	2 years 4 months 2 days
Weighted-average discount rate	7.12%	7.12%
Clinical Trials Expense [Member]
Operating lease expense	$ 240	$ 110
Research and Development Expense [Member]
Operating lease expense	233	284
General and Administrative Expense [Member]
Operating lease expense	$ 243	$ 322

Note 9 - Leases - Schedule of M

Note 9 - Leases - Schedule of Maturity (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
2025	$ 725
2026	243
Total lease payments	968
Less: imputed interest	(55)
Present value of lease payments	$ 913	$ 1,543

Note 10 - Stockholders' Defic_3

Note 10 - Stockholders' Deficit (Details Textual) - USD ($) $ / shares in Units, $ in Thousands									12 Months Ended
	Nov. 01, 2024	Sep. 27, 2024	Jun. 21, 2024	Mar. 28, 2024	Jul. 18, 2023	Jun. 02, 2023	May 24, 2023	Apr. 02, 2023	Dec. 31, 2023	Dec. 31, 2024	Oct. 23, 2022	Jul. 02, 2021	Oct. 15, 2020
Preferred Stock, Shares Authorized (in shares)									60,000,000	60,000,000
Preferred Stock, Shares Issued (in shares)									14,000	36,835
Common Stock, Par or Stated Value Per Share (in dollars per share)									$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding (in shares)									14,000	36,835
Standby Equity Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						100,000	97,000
Stock Purchase Agreement, Value of Shares Authorized for Issuance											$ 8,000
Shares Issued, Price Per Share (in dollars per share)						$ 2.82	$ 3.89
Stock Issued During Period, Value, New Issues						$ 282	$ 377		$ 659
Class of Warrant or Right, October 14, 2025 Expiration [Member]
Warrants and Rights Outstanding, Term (Year)													5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													2,083
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 450
Class of Warrant or Right, July 1, 2026 Expiration [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												13,333
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 187.5
Series A-1 Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									24,000,000	24,000,000
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									16,500,000	16,500,000
Preferred Stock, Shares Issued (in shares)									0	0
Preferred Stock, Shares Outstanding (in shares)									0	0
Series C Convertible Voting Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									14,000	0
Stock Issued During Period, Shares, New Issues (in shares)					6,000			8,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)										$ 6.5
Preferred Stock, Dividend Rate, Percentage									25%
Series D Convertible Voting Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									0	20,000
Stock Issued During Period, Shares, New Issues (in shares)			8,837.58	8,000
Preferred Stock, Convertible, Conversion Price (in dollars per share)										$ 2.5
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)									0	6,000
Stock Issued During Period, Shares, New Issues (in shares)	3,000	2,997
Price of Convertible Preferred Stock to Common Stock, Percentage										80%
Series C & D Preferred Stock [Member] | Kiromic BioPharma Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner										19.99%

Note 10 - Stockholders' Defic_4

Note 10 - Stockholders' Deficit - Preferred Shares (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Dividends	$ 6,530	$ 2,206
Liquidation preference	45,569	16,205
Series C Convertible Voting Preferred Stock [Member]
Dividends	3,510	2,206
Liquidation preference	19,715	16,205
Series D Convertible Voting Preferred Stock [Member]
Dividends	2,698	0
Liquidation preference	19,535	0
Series E Convertible Voting Preferred Stock [Member]
Dividends	322	0
Liquidation preference	$ 6,319	$ 0

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
The 2017 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 0	$ 0
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 0
The 2017 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	1 month 9 days
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 1
Share-Based Payment Arrangement, Expense	24	58
The 2017 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense	$ 0	0
The 2021 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	2 years 7 months 17 days
Share-Based Payment Arrangement, Expense	$ 83	$ 83
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 192
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released in Period (in shares)	49,088
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted But Unreleased In Period (in shares)	95,444
The 2021 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | Granted in 2023 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released in Period (in shares)		45,588
The 2021 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | Granted in 2024 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released in Period (in shares)	3,500
The 2021 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	2 months 26 days
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 126
Share-Based Payment Arrangement, Expense	$ 490	$ 0
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)	28,461

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
The 2017 Stock Incentive Plan [Member]
Outstanding RSUs at beginning of period (in shares)	320	650
Outstanding RSUs at beginning of period (in dollars per share)	$ 285.36	$ 259.5
Granted, shares (in shares)	0	0
Granted, weighted average grant date fair value (in dollars per share)	$ 0	$ 0
Vested, shares (in shares)	(64)	(273)
Vested, weighted average grant date fair value (in dollars per share)	$ 260.18	$ 255.85
Cancelled and forfeited, shares (in shares)	(252)	(57)
Cancelled and forfeited, weighted average grant date fair value (in dollars per share)	$ 254.1	$ 260.1
Nonvested RSUs as of December 31 (in shares)	4	320
Nonvested RSUs as of December 31 (in dollars per share)	$ 257.1	$ 285.36
The 2021 Stock Incentive Plan [Member]
Outstanding RSUs at beginning of period (in shares)	54,706	684
Outstanding RSUs at beginning of period (in dollars per share)	$ 1.56	$ 133.2
Granted, shares (in shares)	98,944	138,343
Granted, weighted average grant date fair value (in dollars per share)	$ 2.58	$ 1.45
Vested, shares (in shares)	(22,332)	(83,700)
Vested, weighted average grant date fair value (in dollars per share)	$ 4.11	$ 0.23
Cancelled and forfeited, shares (in shares)	(73,116)	(621)
Cancelled and forfeited, weighted average grant date fair value (in dollars per share)	$ 1.9	$ 126.6
Nonvested RSUs as of December 31 (in shares)	58,202	54,706
Nonvested RSUs as of December 31 (in dollars per share)	$ 3.63	$ 1.56

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Schedule of Stock Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Restricted Stock [Member] | The 2021 Stock Incentive Plan [Member]
Stock compensation expense	$ 490	$ 0
Restricted Stock [Member] | The 2021 Stock Incentive Plan [Member] | Clinical Trials Expense [Member]
Stock compensation expense	72	0
Restricted Stock [Member] | The 2021 Stock Incentive Plan [Member] | Research and Development Expense [Member]
Stock compensation expense	110	0
Restricted Stock [Member] | The 2021 Stock Incentive Plan [Member] | General and Administrative Expense [Member]
Stock compensation expense	308	0
Restricted Stock Units (RSUs) [Member] | The 2021 Stock Incentive Plan [Member]
Stock compensation expense	83	83
Restricted Stock Units (RSUs) [Member] | The 2021 Stock Incentive Plan [Member] | Clinical Trials Expense [Member]
Stock compensation expense	32	11
Restricted Stock Units (RSUs) [Member] | The 2021 Stock Incentive Plan [Member] | Research and Development Expense [Member]
Stock compensation expense	26	27
Restricted Stock Units (RSUs) [Member] | The 2021 Stock Incentive Plan [Member] | General and Administrative Expense [Member]
Stock compensation expense	25	45
Restricted Stock Units (RSUs) [Member] | The 2017 Stock Incentive Plan [Member]
Stock compensation expense	24	58
Restricted Stock Units (RSUs) [Member] | The 2017 Stock Incentive Plan [Member] | Clinical Trials Expense [Member]
Stock compensation expense	1	7
Restricted Stock Units (RSUs) [Member] | The 2017 Stock Incentive Plan [Member] | Research and Development Expense [Member]
Stock compensation expense	8	19
Restricted Stock Units (RSUs) [Member] | The 2017 Stock Incentive Plan [Member] | General and Administrative Expense [Member]
Stock compensation expense	$ 15	$ 32

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Schedule of Stock Options (Details) - The 2017 Stock Incentive Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Options outstanding, balance (in shares)	18,093	32,706
Options outstanding, balance, weighted average exercise price (in dollars per share)	$ 101.04	$ 96.24
Granted (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)	$ 0	$ 0
Exercised (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Cancelled and forfeited (in shares)	(4,372)	(14,613)
Cancelled and forfeited, weighted average exercise price (in dollars per share)	$ 101.04	$ 88.17
Options outstanding, balance (in shares)	13,721	18,093
Options outstanding, balance, weighted average exercise price (in dollars per share)	$ 101.04	$ 101.04
Options exercisable as of December 31: (in shares)	13,721	18,093
Options exercisable, weighted average exercise price (in dollars per share)	$ 101.04	$ 101.04

Note 11 - Stock-based Compens_7

Note 11 - Stock-based Compensation - Schedule of Restricted Stock (Details) - The 2021 Stock Incentive Plan [Member]	12 Months Ended
	Dec. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares
Options outstanding, balance (in shares)	0	0
Options outstanding, balance, weighted average exercise price (in dollars per share) | $ / shares	$ 0	$ 0
Vested (in shares)	(50,361)	0
Vested, weighted average exercise price	2.47	0
Options outstanding, balance (in shares)	203,824	0
Options outstanding, balance, weighted average exercise price (in dollars per share) | $ / shares	$ 2.41	$ 0
Restricted Stock [Member]
Granted, shares (in shares)	254,185	0
Granted, weighted average grant date fair value (in dollars per share) | $ / shares	$ 2.42	$ 0
Cancelled and forfeited, shares (in shares)	0	0
Cancelled and forfeited, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0	$ 0

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit)	$ 0	$ 0
Operating Loss Carryforwards	92,950	77,040
Net Operating Loss Carryforwards, Subject to Expiration	6,130
Net Operating Loss Carryforwards, Not Subject to Expiration	86,820
Unrecognized Tax Benefits	$ 0	$ 0

Note 12 - Income Taxes - Schedu

Note 12 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Federal income tax at statutory rates	21%	21%
Federal income tax rate reduction	0%	0%
Change in valuation allowance	(21.00%)	(21.00%)
Effective income tax rate	0%	0%

Note 12 - Income Taxes - Sche_2

Note 12 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Net operating loss carryforward	$ 19,519	$ 16,178
Stock compensation expense	517	471
Research and development tax credit	2,615	2,156
Sec. 174 Research and development expense	4,991	3,207
Property and equipment	482	260
Intangible assets	75	82
Lease liability	192	324
Accrued expenses	327	139
Total gross deferred tax assets	28,718	22,817
Valuation allowance	(28,526)	(22,493)
Right-of-use assets	$ (192)	$ (324)

Note 13 - Company 401-K Plan (D

Note 13 - Company 401-K Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 265	$ 221

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Jan. 28, 2025	Dec. 31, 2024	Dec. 31, 2023
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001	$ 0.001
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001
Senior Secured Convertible Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage		25%
Debt Instrument, Face Amount		$ 47.2	$ 28
Debt Instrument, Term (Month)		1 year
Debt Instrument, Interest Rate, Maximum Default Percentage		27%
Senior Secured Convertible Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage	25%
Debt Instrument, Face Amount	$ 1
Debt Instrument, Term (Month)	365 years
Debt Instrument, Interest Rate, Maximum Default Percentage	27%
Debt Instrument, Convertible, Conversion Price, Percentage of VWAP	90%
Percentage of Ownership Limitation	19.99%